Ovarian Cancer

Oliver Dorigo, MD, PhD, discusses the promise of immunotherapy in ovarian cancer.

Jonathan S. Berek, MD, MMS, outlines the changing paradigm of ovarian cancer.

Elisabeth Diver, MD, discusses ongoing advances with PARP inhibitors in ovarian cancer.

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses PARP inhibitors being tested in clinical trials.

Avelumab (Bavencio) alone or in combination with pegylated liposomal doxorubicin did not induce a statistically significant improvement in overall survival or progression-free survival versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/-refractory ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the future of treatment for patients with ovarian cancer.

Diana P. English, MD, discusses the promise for ADCs in the landscape of ovarian cancer treatment and targeting p53 mutations in patients with ovarian cancer.

The combination regimen of pegylated liposomal doxorubicin with bevacizumab was found to significantly improve progression-free survival versus carboplatin/gemcitabine in select patients with recurrent ovarian cancer.

Long-term maintenance therapy with olaparib (Lynparza) tablets demonstrated a low rate of treatment discontinuation and tolerable safety profile in patients with platinum-sensitive recurrent ovarian cancer.

Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.

Oliver Dorigo, MD, PhD, associate professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Medicine, discusses the use of immunotherapy in the treatment of patients with ovarian cancer.

Results of the phase III CORAIL trial demonstrated that the marine-derived treatment lurbinectedin did not improve progression-free survival compared with pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer.

The FDA has granted a priority review designation to a supplemental new drug application for olaparib tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Real-world incidences of nausea, thrombocytopenia, and fatigue were markedly lower in patients with platinum-sensitive, recurrent ovarian cancer receiving a starting 200-mg daily dose of niraparib versus those enrolled on the phase III ENGOT-OV6/NOVA trial.